Studieoverzicht

Study name: ARTEMIDE-01

Histology NSCLC
Tumor stage Stage IV
Host / recruiting sites LUMC
Enrollment Closed
Therapy line First line (1L) ,  Later line (≥2L)
Design

Open label, fase 1/ 2 dosis escalatie en expansie studie

Intervention

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody (Rilvegostomig)

Key outcome parameters

Safety en tolerability, ORR, PFS

Key inclusion criteria

Stadium IV NSCLC, ECOG 0-1

Part C: CPI-naiëf stadium IV NSCLC met PDL1 ≥1%

Part D: CPI-naiëf stadium IV NSCLC met PDL1 ≥50%

Key exclusion criteria

Driver mutatie

Symptomatische CNS metastasen

Steroiden (equivalent >10mg prednisone)

Contact information